It does not mean any change in the 4,000 inspectors assigned by FDA to inspect domestic and foreign facilities or to respond to consumer complaints. However, it does mean the Office of Regulatory Affairs (ORA) will no longer follow district office boundaries leading up to five regional bosses.

Instead, inspectors will specialize on pharmaceuticals, medical devices, tobacco, biological drugs (made from living organisms including vaccines), protected research and data quality, and food.

The change has been four years in the making and the inspector reassignments are intended to help FDA implement the Food Safety Modernizaton Act (FSMA).

The FDA says “program alignment” would allow inspectors to be “more specialized in their work where appropriate and modify certain processes with the goal of improved cross-agency communication, collaboration, and clarity in roles an responsibility.”

Read more about the FDA inspector change HERE.